Peptide Therapeutics Market to Grow at 6.75% CAGR through 2029

Advancements in research & technology and rising prevalence of chronic diseases is expected to drive the Global Peptide Therapeutics Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Peptide Therapeutics Market – Global Industry Size, Share, Trends, Competition, Forecast & Opportunities, 2019-2029F”, the Global Peptide Therapeutics Market stood at USD 42.78 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.75% through 2029. This can be ascribed to rising investment in biopharmaceutical research. In the ever-evolving landscape of healthcare, biopharmaceutical research stands as a powerful engine of innovation, driving the development of novel treatments for a wide array of diseases. Among the emerging frontiers in this realm, the global peptide therapeutics market has been steadily gaining prominence. The symbiotic relationship between robust investment in biopharmaceutical research and the growth of this market is undeniable.

In the dynamic landscape of pharmaceuticals and healthcare, regulatory support and approvals also play a pivotal role in shaping the success and growth of innovative treatments. Among the emerging frontiers of medical advancements, the global peptide therapeutics market is steadily gaining momentum. Regulatory agencies' endorsement of peptide-based drugs signifies a critical turning point for this market's expansion. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and their counterparts globally, are entrusted with safeguarding public health by ensuring that new drugs are safe, effective, and of high quality. Regulatory approval is the culmination of a rigorous evaluation process that involves comprehensive assessments of preclinical and clinical data, manufacturing processes, and risk-benefit profiles. The endorsement of regulatory agencies holds immense significance for the global peptide therapeutics market. When a peptide-based drug receives regulatory approval, it signifies that the treatment has met stringent safety and efficacy standards. This validation not only instills confidence in healthcare providers and patients but also bolsters the credibility of the entire market. Regulatory approval represents the green light for a peptide therapeutic to enter the market and be accessible to patients in need. It is the culmination of years of research, development, and testing. With regulatory barriers overcome, companies can focus on scaling up production, distribution, and marketing efforts. The prospect of regulatory approval acts as a magnet for investment in the development of peptide therapeutics. Investors, ranging from pharmaceutical companies to venture capitalists, are more likely to commit resources to a product with a higher likelihood of making it to market. Regulatory support thus fuels financial backing, facilitating the necessary funding for research and development.

The global peptide therapeutics market, brimming with potential for addressing complex diseases, holds promise as a transformative force in healthcare. However, as with any burgeoning field, it encounters a series of challenges that require innovative solutions. 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Peptide Therapeutics Market”

The Global Peptide Therapeutics Market is segmented into application, type, type of manufacturers, route of administration, synthesis technology, regional distribution, and company.

Based on route of administration, the global peptide therapeutics market can be segmented into parenteral route, oral route, pulmonary, mucosal, and others. The parenteral method of administration dominated the market in 2023. This is mostly because of the widespread adoption, quick drug delivery, and simplicity of use. The industry titans in biopharmaceuticals are constantly looking at novel approaches to peptide-relevant drug delivery. Parenteral administration routes, such as injection or infusion, bypass the digestive system and deliver peptides directly into the bloodstream, ensuring rapid absorption and maximum bioavailability. This allows for precise dosing and consistent therapeutic effects, making parenteral administration the preferred route for many peptide drugs. Parenteral administration offers greater control over drug delivery kinetics, allowing for immediate onset of action and sustained plasma concentrations over an extended period. This is particularly important for peptides with short half-lives or those requiring continuous infusion, such as insulin for diabetes management or peptide hormones for growth disorders.

Based on region, Europe emerged as the second dominant region in the global peptide therapeutics market, following North America. In 2023, Europe accounted for a significant share of the market revenue, driven by several factors contributing to the region's robust growth in this sector. One key factor is Europe's strong pharmaceutical industry, supported by advanced research infrastructure, academic institutions, and a favourable regulatory environment conducive to innovation. European pharmaceutical companies are actively engaged in peptide drug development, leveraging cutting-edge technologies and expertise to advance novel therapeutics for various diseases.

Europe benefits from a well-established healthcare system and high healthcare expenditures, facilitating widespread access to peptide-based treatments. The region's aging population and increasing prevalence of chronic diseases further fuel the demand for innovative therapies, including peptide drugs, to address unmet medical needs effectively. Collaborations between academic research institutions, biotechnology firms, and pharmaceutical companies drive innovation and accelerate the development of peptide therapeutics in Europe. These partnerships foster interdisciplinary research and translational efforts, leading to the discovery and advancement of promising peptide-based treatments across a range of therapeutic areas. Supportive government initiatives and funding programs aimed at promoting biomedical research and fostering innovation contribute to the growth of the peptide therapeutics market in Europe. By fostering a conducive ecosystem for research and development, Europe remains a key player in driving advancements and shaping the future landscape of peptide-based therapies on a global scale. 

Major companies operating in Global Peptide Therapeutics Market are:

• Eli Lilly and Co.
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Co Ltd.
• AstraZeneca Pharmaceuticals LP
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• F Hoffmann-La Roche AG
• Novartis AG
• Novo Nordisk A/S 

Download Free Sample Report

Customers can also request for 10% free customization on this report

“Peptide therapeutics are increasingly recognized for their potential to address orphan diseases and rare disorders that have historically lacked effective treatment options. Their precision targeting and customizable nature make peptides particularly well-suited for tackling the unique challenges posed by these conditions. Unlike traditional pharmaceuticals, peptides can be tailored to interact selectively with specific molecular targets, offering a level of precision and efficacy that is often unmatched by other therapeutic modalities. As a result, researchers and pharmaceutical companies are increasingly turning to peptide-based therapies to develop innovative solutions for rare diseases, providing hope for patients who previously had limited or no treatment options available. This focus on addressing unmet medical needs in the realm of rare disorders is driving the growth of the global peptide therapeutics market, as stakeholders recognize the significant potential of peptides to make a meaningful impact in improving patient outcomes and quality of life.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Peptide Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others), By Type (Generic, Innovative), By Type of Manufacturers (In-house, Outsourced), By Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others), By Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology), By Region 7Competition, 2019-2029F”, has evaluated the future growth potential of Global Peptide Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Peptide Therapeutics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com